Sigyn Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

STOCKHOLDERS??? DEFICIT (Details Narrative)

STOCKHOLDERS’ DEFICIT (Details Narrative) - USD ($)						3 Months Ended			9 Months Ended		12 Months Ended
STOCKHOLDERS’ DEFICIT (Details Narrative) - USD ($)	Apr. 10, 2024	Apr. 09, 2024	Jan. 19, 2024	Jan. 09, 2024	Jun. 02, 2023	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Sep. 05, 2024	Aug. 24, 2024
Class of Stock [Line Items]
Preferred stock, shares authorized						10,000,000			10,000,000		10,000,000
Preferred stock, par value						$ 0.0001			$ 0.0001		$ 0.0001
Preferred stock shares issued						1,148			1,148		32
Preferred stock shares outstanding						1,148			1,148		32
Stock issued during the period Value
Common stock, shares authorized						1,000,000,000			1,000,000,000		1,000,000,000
Common stock, par value						$ 0.0001			$ 0.0001		$ 0.0001
Common stock, shares outstanding						1,420,678			1,420,678		1,288,415
Original issue discount amount						$ 707,730			$ 707,730
Debt conversion, shares issued									157,526
Number of stock issued shares									38,325
Number of stock issued value									$ 214,550
Aggregate number of warrants to purchase shares											559,839
Aggregate principal amount					$ 198,000
Shares cancelled				64,100
Restricted stock											$ 50,000
Share based compensation						$ 37,500	37,500		$ 112,500	$ 112,500
Reverse stock split			one-for-forty reverse stock split
Modification of warrants											352,965
Common Stock [Member]
Class of Stock [Line Items]
Stock issued during the period Value							$ (1)	$ (15)
Conversion of common stock for Series A preferred stock, shares							(9,045)	(152,638)
Debt conversion, shares issued					31,075
Aggregate number of warrants to purchase shares											279,920
Warrant [Member]
Class of Stock [Line Items]
Warrants issued													3,325
Warrants value													$ 15,703
Exercise price												$ 7.50
Warrants value												24,770
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares issued											32
Conversion of common stock for Series A preferred stock, shares											161,684
Preferred stock conversion, description											Each Series B Convertible Preferred Share converts into 126.63 shares of the Company’s common stock, subject to antidilution adjustments for any stock splits and recapitalizations, and for issuances of additional shares at an issue price of less than the conversion ratio in the Warrant Exchange Agreement.
Series B Preferred Stock [Member] \| Convertible Promissory Note [Member] \| Osher Capital Partners LLC [Member]
Class of Stock [Line Items]
Stock issued during the period Value	$ 621,000
Conversion of common stock for Series A preferred stock, shares	823.86
Series B Preferred Stock [Member] \| Convertible Promissory Note [Member] \| Brio Capital Master Fund Ltd. [Member]
Class of Stock [Line Items]
Stock issued during the period Value		$ 220,420
Conversion of common stock for Series A preferred stock, shares		292.4
Common Stock [Member] \| Convertible Promissory Note [Member] \| Osher Capital Partner LLC [Member]
Class of Stock [Line Items]
Conversion of common stock for Series A preferred stock, shares	125.63
Common Stock [Member] \| Convertible Promissory Note [Member] \| Brio Capital Master Fund Ltd. [Member]
Class of Stock [Line Items]
Conversion of common stock for Series A preferred stock, shares		125.63